Medicure Completes Strategic Acquisition of Gateway Medical Pharmacy

Medicure ( (TSE:MPH) ) has provided an update.

Medicure Inc. has completed the acquisition of Gateway Medical Pharmacy, located in Portland, Oregon, through its U.S. subsidiary, Medicure Pharma Inc. This strategic move is part of Medicure’s plan to expand its direct-to-consumer pharmacy business, enhancing growth prospects for its products like ZYPITAMAG®. The acquisition did not involve any financing or debt, and no finder fees were paid, indicating a financially prudent transaction. This acquisition positions Medicure to strengthen its market presence and potentially improve service delivery in the healthcare sector.

More about Medicure

Medicure Inc. is a company dedicated to the development and commercialization of pharmaceuticals and healthcare products, primarily targeting the United States market. The company focuses on marketing and distributing AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets through its U.S. subsidiary, Medicure Pharma Inc. Additionally, Medicure operates Marley Drug Inc., a pharmacy subsidiary that provides medication access across all 50 states, Washington D.C., and Puerto Rico, emphasizing exceptional customer service and free home delivery.

YTD Price Performance: -20.21%

Average Trading Volume: 3,921

Technical Sentiment Consensus Rating: Buy

Current Market Cap: C$7.83M

See more insights into MPH stock on TipRanks’ Stock Analysis page.